New Tablet Formulation and Dosing Regimen of Balsalazide Disodium in Mildly to Moderately Active Ulcerative Colitis
Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to establish the efficacy and safety of a new tablet formulation
and dosing regimen of balsalazide disodium dosed twice daily in achieving clinical
improvement in subjects with mildly to moderately active ulcerative colitis after 8 weeks of
therapy.
Phase:
Phase 3
Details
Lead Sponsor:
Bausch Health Americas, Inc. Valeant Pharmaceuticals International, Inc.